Stephens Inc. AR Cuts Position in Doximity, Inc. (NASDAQ:DOCS)

Stephens Inc. AR decreased its position in shares of Doximity, Inc. (NASDAQ:DOCS) by 21.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,662 shares of the company’s stock after selling 1,239 shares during the period. Stephens Inc. AR’s holdings in Doximity were worth $249,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in DOCS. UMB Bank n.a. raised its holdings in shares of Doximity by 69.1% during the 4th quarter. UMB Bank n.a. now owns 575 shares of the company’s stock valued at $31,000 after buying an additional 235 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Doximity by 324.2% during the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock worth $34,000 after acquiring an additional 603 shares in the last quarter. Morse Asset Management Inc bought a new stake in shares of Doximity in the 3rd quarter worth approximately $46,000. Covestor Ltd boosted its stake in shares of Doximity by 441.9% in the 3rd quarter. Covestor Ltd now owns 1,680 shares of the company’s stock valued at $73,000 after purchasing an additional 1,370 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its holdings in shares of Doximity by 22.5% during the 3rd quarter. First Horizon Advisors Inc. now owns 2,094 shares of the company’s stock valued at $91,000 after purchasing an additional 384 shares during the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity Price Performance

Shares of NASDAQ DOCS opened at $77.13 on Monday. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $85.21. The stock has a market capitalization of $14.40 billion, a P/E ratio of 77.13, a P/E/G ratio of 4.61 and a beta of 1.39. The company’s 50-day moving average is $57.89 and its 200 day moving average is $47.64.

Wall Street Analysts Forecast Growth

DOCS has been the subject of several recent research reports. Barclays boosted their price target on shares of Doximity from $52.00 to $75.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Raymond James reissued an “outperform” rating and issued a $83.00 target price (up previously from $65.00) on shares of Doximity in a research note on Friday, February 7th. Leerink Partnrs upgraded Doximity from a “hold” rating to a “strong-buy” rating in a report on Friday, February 7th. Piper Sandler raised Doximity from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $31.00 to $78.00 in a research note on Friday, February 7th. Finally, Leerink Partners raised Doximity from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $60.00 to $90.00 in a research note on Friday, February 7th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.22.

Insider Buying and Selling at Doximity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the transaction, the director now owns 6,360 shares of the company’s stock, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 37.40% of the company’s stock.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.